Vardah Gill
2 min read
In This Article:
Gilead Sciences, Inc. (NASDAQ:GILD) plans to present over 20 research abstracts—spanning both Gilead and its cell therapy unit Kite—at two major medical conferences: the 2025 ASCO Annual Meeting (May 30–June 3) and the 2025 EHA Congress (June 12–15). The presentations will cover a range of cancers, including breast cancer, solid tumors, and various blood cancers.
A key highlight at ASCO will be late-breaking Phase 3 results from the ASCENT-04 trial, showing that a combination of Trodelvy® and Keytruda® significantly improves progression-free survival compared to Keytruda and standard chemotherapy in patients with PD-L1-positive, inoperable or metastatic triple-negative breast cancer.
Additionally, researchers from the University of Pennsylvania’s Perelman School of Medicine—collaborating with Kite—will share Phase 1 findings on a new CAR T-cell therapy that targets two markers in patients with recurrent glioblastoma, one of the most aggressive brain cancers. These results will be presented during an oral session at ASCO.
Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences, made the following comment in this regard:
“Our oncology portfolio is broad and diverse by design, as we continue to innovate with next-generation therapies and combinations to deliver improved outcomes and ultimately seek to transform how cancer is treated. Data at ASCO and EHA will feature novel pipeline approaches with antibody-drug conjugate therapy and cell therapy, helping to drive oncology innovation and change medical practice.”
While Gilead Sciences, Inc. (NASDAQ:GILD)’s cancer drug pipeline seems promising, the company also didn’t disappoint investors on its financial front. The company is a strong dividend payer, currently offering a quarterly dividend of $0.79 per share. It has also raised its payouts every year since 2015. The stock’s dividend yield comes in at 3.08%, as of May 18. In addition, it is outperforming the broader market this year, surging by nearly 51% since the start of 2025.
While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Mid-Cap Dividend Aristocrats to Invest in Now and 25 High Dividend Stocks Being Targeted By Short Sellers
Disclosure. None.
